• 摘要:
      目的 为免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)超说明书用药提供参考,促进ICIs临床合理用药。
      方法 组建多学科的专家团队,在循证证据的基础上,通过多轮专家研讨,形成ICIs超说明书用药实践指南。
      结果 共纳入有充分循证证据支持的超说明书用药条目212条,其中CTL-A4抑制剂20条,PD-1抑制剂179条,PD-L1抑制剂13条。
      结论 本指南明确了循证证据充分的ICIs超说明书用药范围,为ICIs的超说明书用药管理提供了实用的参考资料。

       

      Abstract:
      OBJECTIVE To provide reference for the off-label use of immune checkpoint inhibitor(ICIs), and to promote the clinical rational use of ICIs.
      METHODS A multi-disciplinary expert team was set up, and the practice guidelines was formed through many rounds of expert discussion on the basis of evidence-based medicine.
      RESULTS A total of 212 items of off-label use supported by sufficient evidence were included, including 20 items about CTL-A4 inhibitors, 179 items about PD-1 inhibitors and 13 items about PD-L1 inhibitors.
      CONCLUSION This guide clarify the off-label use of ICIs with sufficient evidence, and provides a practical reference for ICIs off-label use management.

       

    /

    返回文章
    返回